1-8 of 8
Norman Wolmark
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial

Eleftherios P. Mamounas, Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner, Peter C. Lucas, Charles E. Geyer, Jr, Louis Fehrenbacher, Stephen K. Chia, Adam M. Brufsky, Janice M. Walshe, Gamini S. Soori, Shaker Dakhil, Soonmyung Paik, Sandra M. Swain, Dennis C. Sgroi, Catherine A. Schnabel, Norman Wolmark
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (9): 1984–1991.
https://doi.org/10.1158/1078-0432.CCR-23-1977
Published: 01 May 2024
View article titled, Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial
Open the PDF for Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial in another window
Includes: Supplementary data
Journal Articles

Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer

Carsten Denkert, Chiara Lambertini, Peter A. Fasching, Katherine L. Pogue-Geile, Max S. Mano, Michael Untch, Norman Wolmark, Chiun-Sheng Huang, Sibylle Loibl, Eleftherios P. Mamounas, Charles E. Geyer, Jr, Peter C. Lucas, Thomas Boulet, Chunyan Song, Gail D. Lewis, Malgorzata Nowicka, Sanne de Haas, Mark Basik
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (8): 1569–1581.
https://doi.org/10.1158/1078-0432.CCR-22-1989
Published: 14 April 2023
View article titled, Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer
Open the PDF for Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast Cancer in another window
Includes: Supplementary data
Journal Articles

Neratinib-Plus-Cetuximab in Quadruple-WT (KRAS, NRAS, BRAF, PIK3CA) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study

Samuel A. Jacobs, James J. Lee, Thomas J. George, James L. Wade, III, Philip J. Stella, Ding Wang, Ashwin R. Sama, Fanny Piette, Katherine L. Pogue-Geile, Rim S. Kim, Patrick G. Gavin, Corey Lipchik, Huichen Feng, Ying Wang, Melanie Finnigan, Brian F. Kiesel, Jan H. Beumer, Norman Wolmark, Peter C. Lucas, Carmen J. Allegra, Ashok Srinivasan
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (6): 1612–1622.
https://doi.org/10.1158/1078-0432.CCR-20-1831
Published: 15 March 2021
View article titled, Neratinib-Plus-Cetuximab in Quadruple-WT (<em>KRAS, NRAS, BRAF, PIK3CA</em>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study
Open the PDF for Neratinib-Plus-Cetuximab in Quadruple-WT (<em>KRAS, NRAS, BRAF, PIK3CA</em>) Metastatic Colorectal Cancer Resistant to Cetuximab or Panitumumab: NSABP FC-7, A Phase Ib Study in another window
Includes: Supplementary data
Journal Articles

NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response

Sandra M. Swain, Gong Tang, Heather Ann Brauer, David S. Goerlitz, Peter C. Lucas, André Robidoux, Brent T. Harris, Hanna Bandos, Yuqi Ren, Charles E. Geyer, Jr, Priya Rastogi, Eleftherios P. Mamounas, Norman Wolmark
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2020) 26 (16): 4233–4241.
https://doi.org/10.1158/1078-0432.CCR-20-0152
Published: 14 August 2020
View article titled, NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response
Open the PDF for NSABP B-41, a Randomized Neoadjuvant Trial: Genes and Signatures Associated with Pathologic Complete Response in another window
Includes: Supplementary data
Journal Articles

Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value

Patrick G. Gavin, Linda H. Colangelo, Debora Fumagalli, Noriko Tanaka, Matthew Y. Remillard, Greg Yothers, Chungyeul Kim, Yusuke Taniyama, Seung Il Kim, Hyun Joo Choi, Nicole L. Blackmon, Corey Lipchik, Nicholas J. Petrelli, Michael J. O'Connell, Norman Wolmark, Soonmyung Paik, Kay L. Pogue-Geile
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (23): 6531–6541.
https://doi.org/10.1158/1078-0432.CCR-12-0605
Published: 29 November 2012
View article titled, Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value
Open the PDF for Mutation Profiling and Microsatellite Instability in Stage II and III Colon Cancer: An Assessment of Their Prognostic and Oxaliplatin Predictive Value in another window
Includes: Supplementary data
Journal Articles

Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials

Matthew P. Goetz, Daniel J. Schaid, D. Lawrence Wickerham, Stephanie Safgren, Taisei Mushiroda, Michiaki Kubo, Anthony Batzler, Joseph P. Costantino, Victor G. Vogel, Soonmyung Paik, Erin E. Carlson, David A. Flockhart, Norman Wolmark, Yusuke Nakamura, Richard M. Weinshilboum, James N. Ingle, Matthew M. Ames
Journal: Clinical Cancer Research
Clin Cancer Res (2011) 17 (21): 6944–6951.
https://doi.org/10.1158/1078-0432.CCR-11-0860
Published: 31 October 2011
View article titled, Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials
Open the PDF for Evaluation of CYP2D6 and Efficacy of Tamoxifen and Raloxifene in Women Treated for Breast Cancer Chemoprevention: Results from the NSABP P1 and P2 Clinical Trials in another window
Includes: Supplementary data
Journal Articles

Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials

Douglas T. Ross, Chung-yeul Kim, Gong Tang, Olga L. Bohn, Rodney A. Beck, Brian Z. Ring, Robert S. Seitz, Soonmyung Paik, Joseph P. Costantino, Norman Wolmark
Journal: Clinical Cancer Research
Clin Cancer Res (2008) 14 (20): 6602–6609.
https://doi.org/10.1158/1078-0432.CCR-08-0647
Published: 16 October 2008
View article titled, Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials
Open the PDF for Chemosensitivity and Stratification by a Five Monoclonal Antibody Immunohistochemistry Test in the NSABP B14 and B20 Trials in another window
Journal Articles

Correlations Among p53, Her-2/neu, and ras Overexpression and Aneuploidy by Multiparameter Flow Cytometry in Human Breast Cancer: Evidence for a Common Phenotypic Evolutionary Pattern in Infiltrating Ductal Carcinomas

Charles A. Smith, Agnese A. Pollice, Ling-Ping Gu, Kathryn A. Brown, Sarita G. Singh, Laura E. Janocko, Ronald Johnson, Thomas Julian, David Hyams, Norman Wolmark, Lillian Sweeney, Jan F. Silverman, Stanley E. Shackney
Journal: Clinical Cancer Research
Clin Cancer Res (2000) 6 (1): 112–126.
Published: 01 January 2000
View article titled, Correlations Among p53, Her-2/neu, and ras Overexpression and Aneuploidy by Multiparameter Flow Cytometry in Human Breast Cancer: Evidence for a Common Phenotypic Evolutionary Pattern in Infiltrating Ductal Carcinomas
Open the PDF for Correlations Among p53, Her-2/neu, and ras Overexpression and Aneuploidy by Multiparameter Flow Cytometry in Human Breast Cancer: Evidence for a Common Phenotypic Evolutionary Pattern in Infiltrating Ductal Carcinomas in another window